Literature DB >> 27748687

Update on pharmacotherapy for stroke and traumatic brain injury recovery during rehabilitation.

Joachim Liepert1.   

Abstract

PURPOSE OF REVIEW: This article evaluates whether specific drugs are able to facilitate motor recovery after stroke or improve the level of consciousness, cognitive, or behavioral symptoms after traumatic brain injury. RECENT
FINDINGS: After stroke, serotonin reuptake inhibitors can enhance restitution of motor functions in depressed as well as in nondepressed patients. Erythropoietin and progesterone administered within hours after moderate to severe traumatic brain injury failed to improve the outcome. A single dose of zolpidem can transiently improve the level of consciousness in patients with vegetative state or minimally conscious state.
SUMMARY: Because of the lack of large randomized controlled trials, evidence is still limited. Currently, most convincing evidence exists for fluoxetine for facilitation of motor recovery early after stroke and for amantadine for acceleration of functional recovery after severe traumatic brain injury. Methylphenidate and acetylcholinesterase inhibitors might enhance cognitive functions after traumatic brain injury. Sufficiently powered studies and the identification of predictors of beneficial drug effects are still needed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27748687     DOI: 10.1097/WCO.0000000000000381

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  4 in total

1.  Neurostimulant use is associated with improved survival in comatose patients after cardiac arrest regardless of electroencephalographic substrate.

Authors:  Alexis Steinberg; Jon C Rittenberger; Maria Baldwin; John Faro; Alexandra Urban; Naoir Zaher; Clifton W Callaway; Jonathan Elmer
Journal:  Resuscitation       Date:  2017-12-05       Impact factor: 5.262

2.  Pharmacotherapy Prescription Trends for Cognitive-Behavioral Disorder in Patients With Brain Injury in Korea.

Authors:  Sungchul Huh; Tae Wan Kim; Jung Hyun Yang; Myung Hoon Moon; Soo-Yeon Kim; Hyun-Yoon Ko
Journal:  Ann Rehabil Med       Date:  2018-02-28

Review 3.  Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology.

Authors:  Jenny E Ozga; Jessica M Povroznik; Elizabeth B Engler-Chiurazzi; Cole Vonder Haar
Journal:  Behav Pharmacol       Date:  2018-10       Impact factor: 2.293

Review 4.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.